» Articles » PMID: 37526897

Linking Heat Shock Protein 70 and Parkin in Parkinson's Disease

Overview
Journal Mol Neurobiol
Date 2023 Aug 1
PMID 37526897
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a neurodegenerative disease that affects millions of elderly people worldwide and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The precise mechanisms underlying the pathogenesis of PD are still not fully understood, but it is well accepted that the misfolding, aggregation, and abnormal degradation of proteins are the key causative factors of PD. Heat shock protein 70 (Hsp70) is a molecular chaperone that participates in the degradation of misfolded and aggregated proteins in living cells and organisms. Parkin, an E3 ubiquitin ligase, participates in the degradation of proteins via the proteasome pathway. Recent studies have indicated that both Hsp70 and Parkin play pivotal roles in PD pathogenesis. In this review, we focus on discussing how dysregulation of Hsp70 and Parkin leads to PD pathogenesis, the interaction between Hsp70 and Parkin in the context of PD and their therapeutic applications in PD.

Citing Articles

Amelioration of Motor Performance and Nigrostriatal Dopamine Cell Volume Using a Novel Far-Infrared Ceramic Blanket in an A53T Alpha-Synuclein Transgenic Parkinson's Disease Mouse Model.

Carrick F, Hernandez L, Sugaya K Curr Issues Mol Biol. 2023; 45(12):9823-9837.

PMID: 38132459 PMC: 10742635. DOI: 10.3390/cimb45120613.


The Role of Immune Dysfunction in Parkinson's Disease Development.

Cossu D, Hatano T, Hattori N Int J Mol Sci. 2023; 24(23).

PMID: 38069088 PMC: 10706591. DOI: 10.3390/ijms242316766.

References
1.
Tolosa E, Garrido A, Scholz S, Poewe W . Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021; 20(5):385-397. PMC: 8185633. DOI: 10.1016/S1474-4422(21)00030-2. View

2.
Jee H . Size dependent classification of heat shock proteins: a mini-review. J Exerc Rehabil. 2016; 12(4):255-9. PMC: 5031383. DOI: 10.12965/jer.1632642.321. View

3.
Chaari A, Hoarau-Vechot J, Ladjimi M . Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease. Int J Biol Macromol. 2013; 60:196-205. DOI: 10.1016/j.ijbiomac.2013.05.032. View

4.
Alam P, Bousset L, Melki R, Otzen D . α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem. 2019; 150(5):522-534. DOI: 10.1111/jnc.14808. View

5.
Sanders L, McCoy J, Hu X, Mastroberardino P, Dickinson B, Chang C . Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol Dis. 2014; 70:214-23. PMC: 4144978. DOI: 10.1016/j.nbd.2014.06.014. View